Life science company Acucort has signed an exclusive licensing and distribution agreement with Canadian company Kye Pharmaceuticals for the drug Zeqmelit in Canada.
The agreement gives Kye the right to register, market and sell Zeqmelit, a fast-dissolving oral film containing dexamethasone. A marketing application is planned for early 2027 and a launch is expected in 2028, subject to regulatory approval.
Acucort will receive an upfront payment as well as the opportunity to receive regulatory and commercial milestone payments. In addition, revenue will be generated from product deliveries and royalties on Kye’s net sales. No amounts were disclosed.
Acucort CEO Jonas Jönmark describes the agreement as an important step in the company’s international expansion.
Zeqmelit is already marketed in Sweden, Denmark, Norway and Finland. The company also has a distribution agreement with Glenmark Pharmaceuticals for six European markets.